drugset
Drugs / PSW-1025
last change May 2024 re-read 3 minutes ago

PSW-1025

also known as \[At-211\]PSMA-5

Other / unclassified

Developed for
prostate cancer
Investigated by
Japan Agency for Medical Research and Development · Osaka University

Trials 1

today NCT06441994 · Ph 1
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06441994 May 2024 → Mar 2027 expected prostate cancer Osaka University Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PSW-1025 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06441994 ↗
Known as \[At-211\]PSMA-5 “PSW-1025 (\[At-211\]PSMA-5) is an alpha-ray-emitting drug labeled with Astatine (At-211) that targets PSMA (Prostate Specific Membrane Antigen).” NCT06441994 ↗
Modality Other / unclassified “PSW-1025 (\[At-211\]PSMA-5) is an alpha-ray-emitting drug labeled with Astatine (At-211)” NCT06441994 ↗
Route Intravenous “PSW-1025 is administered intravenously” NCT06441994 ↗